Quest Diagnostics saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, rising from 88 to 91.
This proprietary rating identifies market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks matches up against the rest of the market.
History shows that the best stocks tend to have an RS Rating north of 80 as they launch their largest price moves.
Here Are 3 Keys For Successful Stock Investing
Quest Diagnostics is now considered extended and out of buy range after clearing a 165.32 buy point in a first-stage cup without handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
In terms of top and bottom line numbers, Quest Diagnostics has posted rising EPS growth in each of the last three reports. Sales growth has also risen over the same time frame.
The company holds the No. 3 rank among its peers in the Medical-Services industry group. Option Care Health is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
